Last reviewed · How we verify
valsartan/amlodpine
Valsartan/amlodipine is a combination of an angiotensin II receptor blocker and a calcium channel blocker that reduces blood pressure through dual vasodilation and reduced vasoconstriction.
Valsartan/amlodipine is a combination of an angiotensin II receptor blocker and a calcium channel blocker that reduces blood pressure through dual vasodilation and reduced vasoconstriction. Used for Hypertension.
At a glance
| Generic name | valsartan/amlodpine |
|---|---|
| Sponsor | University of Pavia |
| Drug class | Angiotensin II receptor blocker / Calcium channel blocker combination |
| Target | AT1 receptor / L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Valsartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone release, thereby lowering blood pressure. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation. Together, these complementary mechanisms provide additive antihypertensive effects.
Approved indications
- Hypertension
Common side effects
- Peripheral edema
- Dizziness
- Fatigue
- Headache
- Flushing
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- valsartan/amlodpine CI brief — competitive landscape report
- valsartan/amlodpine updates RSS · CI watch RSS
- University of Pavia portfolio CI